Colinz Laboratories Ltd (531210)
🎯 Key Takeaways
- Revenue declined 29.1% QoQ to ₹1 in Q1FY27.
- Market Cap
- ₹19
- P/E Ratio
- 6.9
- P/B Ratio
- 1.92
- ROE
- 27.8%
- ROCE
- 33.4%
- Debt/Equity
- 0.04
- Promoter
- 50.6%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1 | 1 | 2 | 1 |
| Operating Profit | 0 | 0 | 0 | 0 |
| OPM % | 2.9% | 4.2% | 2.9% | 1.6% |
| Net Profit | 0 | 0 | 0 | 2 |
| EPS | ₹0.56 | ₹0.33 | ₹0.68 | ₹9.53 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 |
| Reserves | 7 | 7 | 8 | 7 |
| Borrowings | 1 | 1 | 0 | 1 |
| Total Liabilities | 12 | 12 | 13 | 12 |
| Fixed Assets | 2 | 2 | 2 | 2 |
| Investments | 1 | 1 | 1 | 1 |
| Total Assets | 12 | 12 | 13 | 12 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -1 |
| Investing | -0 |
| Financing | +0 |
| Net Cash Flow | -1 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 66.0% | 66.0% | 66.0% | 50.6% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 31.0% | 31.0% | 31.2% | 46.2% |
| # Shareholders | 3,272 | 3,212 | 3,250 | 3,174 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.37 L Cr | 36.1 | 18.7% | — | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.2 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.6 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.16 L Cr | 25.9 | 16.8% | — | 0.43 |
| CIPLA | 1.09 L Cr | 32.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 97.8 | 20.8% | — | 0.45 |
| MANKIND | 1.03 L Cr | 50.6 | 13.9% | — | 0.38 |
| DRREDDY | 1.03 L Cr | 31.9 | 10.1% | — | 0.17 |
| AUROPHARMA | 95,887 | 26.0 | 12.8% | — | 0.20 |
| LUPIN | 93,367 | 16.5 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🟡 related party transaction2026-10-01Colinz Laboratories Ltd declared non-applicability of SEBI LODR Regulation 23(9) related party transaction disclosures for Q3 FY2026, citing exemption…
- 🔴 Corporate Action2026-10-01Colinz Laboratories declared that SEBI's Regulation 32 of the LODR 2015 does not apply to the company for the quarter ended September 30, 2026, as no …
- Announcement2026-09-29Colinz Laboratories Ltd announced the closure of its insider trading window ahead of the quarterly results announcement for the quarter ending Septemb…
- 🟡 voting results2026-09-23The 40th AGM of Colinz Laboratories Limited was held on 22 September 2026, with all resolutions passed by the requisite majority. Remote e-voting and …
- 🟡 Board Meeting2026-09-22Colinz Laboratories held its 40th AGM on September 22, 2026, approving audited financial statements for the year ended March 31, 2026, appointing a ne…
- 🔴 Insider Trading2026-09-04Saffron Capital Advisors disclosed a post-offer advertisement for the open offer by Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, alon…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day